Dyadic International (DYAI)
NASDAQ:DYAI
Want to see DYAI full AI Analyst Report?
DYAI Stock Chart & Stats
$0.93
-$0.19(-9.79%)
At close: 4:00 PM EST
$0.93
-$0.19(-9.79%)
Day’s Range― - ―
52-Week Range$0.65 - $1.35
Previous CloseN/A
Volume131.09K
Average Volume (3M)396.96K
Market Cap
$31.34M
Enterprise Value$30.68M
Total Cash (Recent Filing)$7.32M
Total Debt (Recent Filing)$5.06M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
May 20, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding36,438,700
10 Day Avg. Volume144,364
30 Day Avg. Volume396,964
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)24.88
Price to Sales (P/S)9.92
P/FCF Ratio-5.38
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue9.93
Enterprise Value/Gross Profit12.32
Enterprise Value/Ebitda-4.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$8.47M
Bulls Say, Bears Say
Bulls Say
Platform Validation Via CollaborationsThird-party validation from major institutes and reputable partners reduces technical and commercial risk for the C1 platform. Over the medium term this durable endorsement supports licensing uptake, partner-funded development, regulatory credibility, and a lower-cost route to recurring revenue without heavy capital outlays.
Commercial Product Launches And ChannelsMultiple early commercial product launches and distribution/OEM partnerships shift the company from pure R&D to revenue-generating activity. Durable advantage comes from established sales channels, partner manufacturing, and profit-sharing models that can scale sales without large capex, enabling recurring orders and product-market learning.
Material Non-dilutive Grant FundingSignificant grant receipts provide non-dilutive capital to fund development and operations, extending runway and reducing immediate financing pressure. Grants also validate technology priorities and can accelerate partner programs and qualification steps, supporting a steadier path to recurring, commercial revenue.
Bears Say
Rising Leverage And Weakened Balance SheetA sharp increase in leverage materially reduces financial flexibility and raises refinancing and covenant risk. With a smaller equity cushion, the company has less capacity to absorb shocks or fund growth internally, increasing the probability of dilutive financing or constrained strategic options if cash generation doesn't improve.
Persistent Negative Operating Cash FlowOngoing negative operating cash flow forces dependency on external financing, grants, or partner funding to sustain operations. Structurally weak cash conversion limits the firm’s ability to scale independently, makes long-term planning contingent on successful fundraising, and increases dilution or compromise on strategic choices.
Small Revenue Base And Deep LossesA tiny revenue base paired with deeply negative margins shows operating expenses vastly exceed sales. Durable profitability will require significant and sustained revenue scale; until then the company faces structural operating leverage risk, making margin recovery dependent on successful, sizable commercialization.
Dyadic International News
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $0.65 and its highest was $1.35 in the past 12 months.
What is Dyadic International’s market cap?
Dyadic International’s market cap is $31.34M.
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is May 20, 2026 which is in 22 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on Mar 25, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.045 by $0.005.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Overvalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -0.04.
How many shares outstanding does Dyadic International have?
Dyadic International has 36,438,700 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.045. Following the earnings report the stock price went down -19.61%.
Which hedge fund is a major shareholder of Dyadic International?
Currently, no hedge funds are holding shares in DYAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyadic International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
DYAI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.86%
12-Months-Change
Fundamentals
Return on Equity
-695.82%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress: multiple product launches, distribution and manufacturing partnerships, grant funding, and platform validation through reputable collaborators, signaling a substantive transition toward commercialization. However, near-term financials show declining revenue (-11.7%) and larger losses (+~26.7% net loss increase), with continued cash burn and dependence on partner/grant-driven revenue. Management presents a credible path to scale and a runway into 2027 but acknowledges a measured, gradual revenue ramp as customers qualify products; the strategic progress and non-dilutive funding moderately outweigh short-term financial headwinds.View all DYAI earnings summariesDYAI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
Collplant Holdings
―
Reviva Pharmaceuticals Holdings
―
―
Rani Therapeutics Holdings
―
Ownership Overview
16.31% Insiders
2.81% Mutual Funds
2.57% Other Institutional Investors
75.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---